Antioxidants and Redox Signaling · 2014 · 52 citations · 32 references
MedicineCardiologyPharmacologyInflammationRegenerative MedicineStem Cell TransplantationCardiac RegenerationInflammatory SignalingMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyStem Cell Signaling PathwaysTissue Engineering With Stem CellsAdipose Stem CellsAdipose-derived Mesenchymal Stem CellsAdipose-derived Mesenchymal Stromal CellsLiver X Receptor SignalingMyocardial Infarction RepairMyocardial RegenerationMyocardial RepairVascular Endothelial Growth Factor
AIMS: Clinical application of cellular therapy for cardiac regeneration is significantly hampered by the low retention of engrafted cells, mainly attributable to the poor microenvironment dominated by inflammation and oxidative stress in the host's infarcted myocardium. This study aims at investigating whether liver X receptor (LXR) agonist T0901317 will improve survival of adipose-derived mesenchymal stem cells (AD-MSCs) after transplantation into infarcted hearts. RESULTS: Noninvasive in vivo bioluminescence imaging and histological staining showed that LXR agonist T0901317 improved the retention and survival of intramyocardially injected AD-MSCs. Moreover, combined therapy of LXR agonist and AD-MSCs inhibited host cardiomyocyte apoptosis, reduced fibrosis, and improved cardiac function, while it concomitantly decreased inflammatory cytokines (e.g., tumor necrosis factor-α and interleukin-6) and increased growth factor (e.g., vascular endothelial growth factor and basic fibroblast growth factor) expression in infarct myocardium. To reveal possible mechanisms, AD-MSCs were subjected to hypoxia/serum deprivation (H/SD) injury to simulate ischemic conditions in vivo. The LXR agonist (10(-7) mM) improved AD-MSC survival under H/SD condition. Western blot revealed that the LXR agonist reduced TLR4, TRAF-6, and MyD88 protein expression, inhibited IκBα phosphorylation and NF-κB-p65 nuclear translocation, which resulted in accelerated Keap-1 protein degradation, enhanced Nrf-2 nuclear translocation, and increased HO-1 protein expression. INNOVATION AND CONCLUSION: LXR agonist can enhance the functional survival of transplanted AD-MSCs in infarcted myocardium, at least partially, via modulation of the TLR4/NF-κB and Keap-1/Nrf-2 signaling pathways. Moreover, combined therapy of LXR agonist and AD-MSCs has a synergetic effect on cardiac repair and functional improvement after infarction.
32
Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells
Jalees Rehman, Dmitry O. Traktuev, Jingling Li et al. · Circulation · 2004 · 2.3K citations
Medicine, Cell Biology, Cell Therapy +11
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Bethany A. Janowski, Patricia J. Willy, Thota Rama Devi et al. · Nature · 1996 · 1.7K citations
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
Sean B. Joseph, Antonio Castrillo, Bryan Laffitte et al. · Nature Medicine · 2003 · 1.1K citations
A Novel and Efficient Model of Coronary Artery Ligation and Myocardial Infarction in the Mouse
Erhe Gao, Yong Lei, Xiying Shang et al. · Circulation Research · 2010 · 772 citations
Medicine, Cardiology, Surgery +10